Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Valiant Bio-B (09887) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report by CICC, Valiant Bio-B is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - Valiant Bio-B announced that the first patient has successfully received treatment in the Phase Ib/II clinical study of its PD-L1/4-1BB bispecific antibody, Opalizumab (LBL-024), for recurrent or metastatic triple-negative breast cancer [1] - The open-label, multicenter Phase Ib/II clinical study is led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital and is being conducted simultaneously at multiple hospitals across the country [1] - The trial aims to evaluate the efficacy and safety of Opalizumab as a monotherapy or in combination with albumin-bound paclitaxel for patients with recurrent or metastatic triple-negative breast cancer [1]
维立志博-B获纳入恒生综合指数 有望成为港股通标的